1. EYLEA and Dupixent sales drive company revenue to new records; 2. R&D expenses are projected to reach $5 billion, but the business remains highly profitable; 3. Regeneron is liquid and solvent, but growth rates are falling; 4. The company's value appears overvalued according to quantitative analysis; 5. The author is holding the position for long-term growth and benefits.